In France, the sold production of compounds containing a pyrimidine or piperazine ring is expected to decline significantly from 2024 onwards. The forecast for 2024 is 46.387 million Euros, decreasing steadily each year to 28.866 million Euros by 2028. This represents a downward trend in production value, chiefly driven by various market dynamics. Considering that the value sat at 51.5 million Euros in 2023, the sector faces a notable contraction.

Year-on-year variations indicate a consistent decrease, painting a picture of diminishing growth prospects. Over the 2024-2028 period, a compound annual growth rate (CAGR) reflective of a negative trend is expected.

Looking ahead, watch for:

Regulatory impacts on chemical manufacturing, potentially accelerating declines.
Innovations in pharmaceutical manufacturing, which could alter the demand for these compounds.
Global market conditions influencing production costs and competitiveness.